Skip to main content
Top
Published in: Annals of Hematology 7/2013

01-07-2013 | Original Article

Thrombocytopenia in neonates: causes and outcomes

Authors: Ezgi Ulusoy, Özlem Tüfekçi, Nuray Duman, Abdullah Kumral, Gülersu İrken, Hale Ören

Published in: Annals of Hematology | Issue 7/2013

Login to get access

Abstract

Thrombocytopenia is one of the most common hematological abnormalities found in neonates. The causes, treatment modalities, and outcomes of neonatal thrombocytopenia have to be evaluated for providing better care and follow-up. In this study, our aim was to assess the prevalence, causes, treatment modalities, and outcomes of thrombocytopenia in neonates. A retrospective analysis was conducted on the medical records of all neonates hospitalized at our hospital between January 2007 and December 2011 and those with thrombocytopenia were included in the study. Of the 3,515 neonates, 134 (3.8 %) had thrombocytopenia. Ninety-seven of them (72 %) were preterm. In the patients admitted to neonatal intensive care unit, the prevalence of thrombocytopenia was found as 12 %, whereas it was found as 1.2 % in neonatal service. The highest prevalence was detected in the year 2008 by 5.3 %, and the lowest prevalence was detected in the year 2011 by 2.4 %. Sepsis was the most common etiologic factor between years 2007 and 2009. Intrauterine growth restriction, metabolic disorders, drugs, and asphyxia were more common causes in the recent years. Severe thrombocytopenia was found in 26 % of neonates and 11 % of thrombocytopenic neonates had major hemorrhage. Intracranial hemorrhage ratio was 5.9 % and all of these patients were preterm. Thrombocytopenia improved in 92.5 % of patients and persisted in 3 % of patients. Death occurred in 4.5 % of neonates. This study shows that the causes of neonatal thrombocytopenia may show variations with respect to time and the prevalence, complications, and risks of thrombocytopenia may be lowered by eliminating preventable factors.
Literature
1.
2.
go back to reference Sola-Vishner M, Saxonhouse MA, Brown RE (2008) Neonatal thrombocytopenia: what we do and don't know. Early Hum Dev 84:499–506CrossRef Sola-Vishner M, Saxonhouse MA, Brown RE (2008) Neonatal thrombocytopenia: what we do and don't know. Early Hum Dev 84:499–506CrossRef
3.
go back to reference Roberts I, Murray NA (2003) Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 88:359–364CrossRef Roberts I, Murray NA (2003) Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 88:359–364CrossRef
4.
go back to reference Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G, Immune Thrombocytopenia Working Group (1997) Frequency of immune thrombocytopenia in newborns: a prospective study. Blood 89:4402–4406PubMed Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G, Immune Thrombocytopenia Working Group (1997) Frequency of immune thrombocytopenia in newborns: a prospective study. Blood 89:4402–4406PubMed
5.
go back to reference Stanworth SJ, Clarke P, Watts T, Ballard S, Choo L, Morris T, Murphy MF, Roberts I (2009) Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics 124:826–834CrossRef Stanworth SJ, Clarke P, Watts T, Ballard S, Choo L, Morris T, Murphy MF, Roberts I (2009) Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics 124:826–834CrossRef
6.
go back to reference Oren H, İrken G, Oren B, Olgun N, Ozkan H (1994) Assessment of clinical impact and predisposing factors for neonatal thrombocytopenia. Indian J Pediatr 61:551–558PubMedCrossRef Oren H, İrken G, Oren B, Olgun N, Ozkan H (1994) Assessment of clinical impact and predisposing factors for neonatal thrombocytopenia. Indian J Pediatr 61:551–558PubMedCrossRef
7.
go back to reference Castle V, Andrew M, Kelton J, Giron D, Johnston M, Carter C (1986) Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 108:749–755PubMedCrossRef Castle V, Andrew M, Kelton J, Giron D, Johnston M, Carter C (1986) Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 108:749–755PubMedCrossRef
8.
go back to reference Mehta P, Rohitkumar V, Neumann L et al (1980) Thrombocytopenia in the high risk infant. J Pediatr 97:791–794PubMedCrossRef Mehta P, Rohitkumar V, Neumann L et al (1980) Thrombocytopenia in the high risk infant. J Pediatr 97:791–794PubMedCrossRef
9.
go back to reference Christensen RD, Henry E, Wiedmeier S, Karpatkin M (2006) Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system. J Perinatol 26:348–353PubMedCrossRef Christensen RD, Henry E, Wiedmeier S, Karpatkin M (2006) Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system. J Perinatol 26:348–353PubMedCrossRef
10.
go back to reference Murray NA, Roberts IA (1996) Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates. Pediatr Res 40:112–119PubMedCrossRef Murray NA, Roberts IA (1996) Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates. Pediatr Res 40:112–119PubMedCrossRef
11.
go back to reference Watts TL, Roberts IAG (1999) Hematological abnormalities in the growth-restricted infant. Semin Neonatol 4:41–54CrossRef Watts TL, Roberts IAG (1999) Hematological abnormalities in the growth-restricted infant. Semin Neonatol 4:41–54CrossRef
12.
go back to reference Murray NA, Howarth LJ, McCloy MP, Letsky EA, Roberts IA (2002) Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 12:35–41PubMedCrossRef Murray NA, Howarth LJ, McCloy MP, Letsky EA, Roberts IA (2002) Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 12:35–41PubMedCrossRef
13.
go back to reference Sola MC, Rimsza LM (2002) Mechanisms underlying thrombocytopenia in the neonatal intensive care unit. Acta Pediatrica Suppl 12:35–41 Sola MC, Rimsza LM (2002) Mechanisms underlying thrombocytopenia in the neonatal intensive care unit. Acta Pediatrica Suppl 12:35–41
14.
go back to reference Sallmon H, Sola-Visner M (2012) Clinical and research issues in neonatal anemia and thrombocytopenia. Curr Opin Pediatr 24:16–22PubMedCrossRef Sallmon H, Sola-Visner M (2012) Clinical and research issues in neonatal anemia and thrombocytopenia. Curr Opin Pediatr 24:16–22PubMedCrossRef
15.
go back to reference von Lindern JS, van den Bruele T, Lopriore E, Walther FJ (2011) Thrombocytopenia in neonates and the risk of intraventricular hemorrhage: a retrospective cohort study. BMC Pediatr 11:16–22CrossRef von Lindern JS, van den Bruele T, Lopriore E, Walther FJ (2011) Thrombocytopenia in neonates and the risk of intraventricular hemorrhage: a retrospective cohort study. BMC Pediatr 11:16–22CrossRef
16.
go back to reference Gommella TL (2004) Neonatology: management, procedures, on-call problems, diseases, and drugs, 5th edn. McGraw-Hill, New York Gommella TL (2004) Neonatology: management, procedures, on-call problems, diseases, and drugs, 5th edn. McGraw-Hill, New York
17.
go back to reference Kent AL, Wright IM, Abdel-Latif ME (2012) Mortality and adverse neurologic outcomes are greater in preterm male infants. Pediatrics 129:124–131PubMedCrossRef Kent AL, Wright IM, Abdel-Latif ME (2012) Mortality and adverse neurologic outcomes are greater in preterm male infants. Pediatrics 129:124–131PubMedCrossRef
18.
go back to reference Bhat YR, Cherian CS (2008) Neonatal thrombocytopenia associated with maternal pregnancy induced hypertension. Indian J Pediatr 75:571–573PubMedCrossRef Bhat YR, Cherian CS (2008) Neonatal thrombocytopenia associated with maternal pregnancy induced hypertension. Indian J Pediatr 75:571–573PubMedCrossRef
19.
20.
go back to reference Beachy J (2011) Neonatal alloimmune thrombocytopenia: a case study. Neonatal Net 30:402–407CrossRef Beachy J (2011) Neonatal alloimmune thrombocytopenia: a case study. Neonatal Net 30:402–407CrossRef
21.
go back to reference Uhrynowska M, Niznikowska-Marks M, Zupańska B (2000) Neonatal and maternal thrombocytopenia: incidence and immune background. Eur J Haematol 64:42–46PubMedCrossRef Uhrynowska M, Niznikowska-Marks M, Zupańska B (2000) Neonatal and maternal thrombocytopenia: incidence and immune background. Eur J Haematol 64:42–46PubMedCrossRef
22.
23.
go back to reference Chakravorty S, Roberts I (2012) How I manage neonatal thrombocytopenia. Br J Haematol 156:155–162PubMedCrossRef Chakravorty S, Roberts I (2012) How I manage neonatal thrombocytopenia. Br J Haematol 156:155–162PubMedCrossRef
24.
go back to reference Holzhauer S, Zieger B (2011) Diagnosis and management of neonatal thrombocytopenia. Semin Fetal Neonatal Med 16:305–310PubMedCrossRef Holzhauer S, Zieger B (2011) Diagnosis and management of neonatal thrombocytopenia. Semin Fetal Neonatal Med 16:305–310PubMedCrossRef
25.
go back to reference Christensen RD (2011) Platelet transfusion in the neonatal intensive care unit: benefits, risks, alternatives. Neonatology 100:311–318PubMedCrossRef Christensen RD (2011) Platelet transfusion in the neonatal intensive care unit: benefits, risks, alternatives. Neonatology 100:311–318PubMedCrossRef
26.
go back to reference Sola-Visner M, Sallmon H, Brown R (2009) New insights into the mechanisms of nonimmune thrombocytopenia in neonates. Semin Perinatol 33:43–51PubMedCrossRef Sola-Visner M, Sallmon H, Brown R (2009) New insights into the mechanisms of nonimmune thrombocytopenia in neonates. Semin Perinatol 33:43–51PubMedCrossRef
27.
go back to reference Alexander F, Chiu L, Kroh M, Hammel J, Moore J (2009) Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus. J Pediatr Surg 44:112–117PubMedCrossRef Alexander F, Chiu L, Kroh M, Hammel J, Moore J (2009) Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus. J Pediatr Surg 44:112–117PubMedCrossRef
28.
go back to reference Linder N, Bello R, Hernandez A, Rosen C, Birk E, Sirota L, Pushkov Y, Klinger G (2010) Treatment of patent ductus arteriosus: indomethacin or ibuprofen? Am J Perinatol 27:399–404PubMedCrossRef Linder N, Bello R, Hernandez A, Rosen C, Birk E, Sirota L, Pushkov Y, Klinger G (2010) Treatment of patent ductus arteriosus: indomethacin or ibuprofen? Am J Perinatol 27:399–404PubMedCrossRef
29.
go back to reference Little DC, Pratt TC, Blalock SE, Krauss DR, Cooney DR, Custer MD (2003) Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg 38:492–496PubMedCrossRef Little DC, Pratt TC, Blalock SE, Krauss DR, Cooney DR, Custer MD (2003) Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg 38:492–496PubMedCrossRef
30.
go back to reference Jain S (1994) Ibuprofen-induced thrombocytopenia. Br J Clin Pract 48:51–52PubMed Jain S (1994) Ibuprofen-induced thrombocytopenia. Br J Clin Pract 48:51–52PubMed
31.
go back to reference Murray N, Ballard S, Casbard A (2006) A multi-centre prospective observational study of platelet transfusion practice in neonates with severe thrombocytopenia. Blood 108:287 Murray N, Ballard S, Casbard A (2006) A multi-centre prospective observational study of platelet transfusion practice in neonates with severe thrombocytopenia. Blood 108:287
32.
go back to reference Baer VL, Lambert DK, Henry E, Snow GL, Sola-Visner MC, Christensen RD (2007) Do platelet transfusions in the NICU adversely affect survival? Analysis of 1600 thrombocytopenic neonates in a multihospital healthcare system. J Perinatol 27:790–796PubMedCrossRef Baer VL, Lambert DK, Henry E, Snow GL, Sola-Visner MC, Christensen RD (2007) Do platelet transfusions in the NICU adversely affect survival? Analysis of 1600 thrombocytopenic neonates in a multihospital healthcare system. J Perinatol 27:790–796PubMedCrossRef
33.
go back to reference Garcia MG, Duenas E, Sola MC, Hutson AD, Theriaque D, Christensen RD (2001) Epidemiologic and outcome studies of patients who received platelet transfusions in the neonatal intensive care unit. J Perinatol 21:415–420PubMedCrossRef Garcia MG, Duenas E, Sola MC, Hutson AD, Theriaque D, Christensen RD (2001) Epidemiologic and outcome studies of patients who received platelet transfusions in the neonatal intensive care unit. J Perinatol 21:415–420PubMedCrossRef
34.
go back to reference Del Vecchio A, Sola MC, Theriaque DW, Hutson AD, Kao KJ, Wright D, Garcia MG, Pollock BH, Christensen RD (2001) Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions. Transfusion 41:803–808PubMedCrossRef Del Vecchio A, Sola MC, Theriaque DW, Hutson AD, Kao KJ, Wright D, Garcia MG, Pollock BH, Christensen RD (2001) Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions. Transfusion 41:803–808PubMedCrossRef
35.
go back to reference Christensen RD, Henry E, Del Vecchio A (2012) Thrombocytosis and thrombocytopenia in the NICU: incidence, mechanisms and treatments. J Matern Fetal Neonatal Med 25:15–17PubMed Christensen RD, Henry E, Del Vecchio A (2012) Thrombocytosis and thrombocytopenia in the NICU: incidence, mechanisms and treatments. J Matern Fetal Neonatal Med 25:15–17PubMed
Metadata
Title
Thrombocytopenia in neonates: causes and outcomes
Authors
Ezgi Ulusoy
Özlem Tüfekçi
Nuray Duman
Abdullah Kumral
Gülersu İrken
Hale Ören
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 7/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1726-0

Other articles of this Issue 7/2013

Annals of Hematology 7/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.